Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
Adding peptides into your daily groove can revitalize different bits of your well-being
doi:10.1155/2015/648108 Sakuma S, Ishimura M, Yuba Y, Itoh Y, Fujimoto Y
The researchers found that the estimated mean change in hemoglobin A1c (HbA1c) after 40 weeks was 1.8, 1.5, and 0.1 percentage points for cagrilintide-semaglutide 2.4 mg each, 1.0 mg each, and placebo, respectively
Under CC 2.0 license